Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature

Omar Al Ustwani; Laurie A. Ford; Sheila J.N. Sait; Anne Marie W. Block; Maurice Barcos; Carlos E. Vigil; Elizabeth A. Griffiths; James E. Thompson; Eunice S. Wang; Julian Ambrus; Meir Wetzler

doi:10.1016/j.leukres.2013.04.007

Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature

Omar Al Ustwani
, Laurie A. Ford
, Sheila J.N. Sait
, Anne Marie W. Block
, Maurice Barcos
, Carlos E. Vigil
, Elizabeth A. Griffiths
, James E. Thompson
, Eunice S. Wang
, Julian Ambrus
, Meir Wetzler

Roswell Park Cancer Institute

Research output: Contribution to journal › Article › peer-review

71 Scopus citations

Abstract

Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.

Original language	English
Pages (from-to)	894-899
Number of pages	6
Journal	Leukemia Research
Volume	37
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2013.04.007
State	Published - Aug 2013

Keywords

Autoimmune diseases
Hypomethylating agents
Myelodysplastic syndrome
Outcome
Treatment

Access to Document

10.1016/j.leukres.2013.04.007

Cite this

@article{257a6c44fca44dfcb26e5c50e2466fb5,

title = "Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature",

abstract = "Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.",

keywords = "Autoimmune diseases, Hypomethylating agents, Myelodysplastic syndrome, Outcome, Treatment",

author = "Ustwani, \{Omar Al\} and Ford, \{Laurie A.\} and Sait, \{Sheila J.N.\} and Block, \{Anne Marie W.\} and Maurice Barcos and Vigil, \{Carlos E.\} and Griffiths, \{Elizabeth A.\} and Thompson, \{James E.\} and Wang, \{Eunice S.\} and Julian Ambrus and Meir Wetzler",

year = "2013",

month = aug,

doi = "10.1016/j.leukres.2013.04.007",

language = "English",

volume = "37",

pages = "894--899",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature

AU - Ustwani, Omar Al

AU - Ford, Laurie A.

AU - Sait, Sheila J.N.

AU - Block, Anne Marie W.

AU - Barcos, Maurice

AU - Vigil, Carlos E.

AU - Griffiths, Elizabeth A.

AU - Thompson, James E.

AU - Wang, Eunice S.

AU - Ambrus, Julian

AU - Wetzler, Meir

PY - 2013/8

Y1 - 2013/8

N2 - Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.

AB - Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.

KW - Autoimmune diseases

KW - Hypomethylating agents

KW - Myelodysplastic syndrome

KW - Outcome

KW - Treatment

UR - https://www.scopus.com/pages/publications/84879779773

U2 - 10.1016/j.leukres.2013.04.007

DO - 10.1016/j.leukres.2013.04.007

M3 - Article

C2 - 23692654

AN - SCOPUS:84879779773

SN - 0145-2126

VL - 37

SP - 894

EP - 899

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this